Friday 1^st March 2019

13:45      Welcome and introduction (D. Betticher, Fribourg)

Targeted therapies, state of the art (D. Betticher, Fribourg)

13:50      EGFR (J. Yang, Taiwan)

14:20      ALK (M. Früh, St. Gallen)

14:50      Others (RAF, ROS, RET) (O. Gautschi, Luzern)

15:20      Case presentations

16:00      Coffee break

Diagnostics (R. Stahel, Zürich)

16:30      Pathology: Identifying targets in lung cancer (I. Letovanec, Lausanne)

17:00      Genomics: present state (L. Bubendorf, Basel)

17:30      Predictors for IO/Immunogram (J. Haanen, Amsterdam)

18:10      Discussion

18:30      Adjourn

Saturday 2^nd March 2019

Immunotherapy (D. Betticher, Fribourg)

08:00      Frontline IO for all? (S. Peters, Lausanne)

08:30      IO for early NSCLC (D. Planchard, Villejuif Cedex)

09:00      New developments (phase I) (S. Zimmermann, Lausanne)

09:30      Case presentations

10:00      Coffee break

Further situations (S. Peters, Lausanne)

10:30      IO for Mesothelioma and SCKC (N. Girard, Paris)

11:00      Other new options for Mesothelioma and SCLC (M. Pless, Winterthur)

11:30      Oligometastastic disease (N. Andratschke, Zürich)

12:00      Wrap up (S. Peters, R. Stahel)

12:15      End